Trump announces landmark trade deal with EU
On Thursday, Bernstein analysts maintained their Market Perform rating for CIGNA Corporation (NYSE:CI) shares, with a price target of $323.00. The endorsement comes as CIGNA, a healthcare giant with $247.12 billion in revenue and an $85.36 billion market cap, announced a strategic leadership change within the company.
Brian Evanko, who has a broad range of experience within CIGNA, having served as CFO and Head of the entire Healthcare business, has taken on a significant role. His previous accomplishments include stabilizing the Medicare business and managing the Individual business unit. Bernstein analysts expressed confidence in Evanko’s capabilities, citing his comprehensive operational and financial expertise as well as his strategic acumen. According to InvestingPro, CIGNA maintains strong financial health with a "GREAT" overall score, suggesting solid operational execution.
The analysts’ statement highlighted Evanko’s track record, emphasizing his strength as an operator and leader. They noted, "We are positive on this move. Brian Evanko is a strong operator and leader with experience across the enterprise." InvestingPro analysis reveals the company has been consistently rewarding shareholders with a 1.94% dividend yield and has maintained dividend payments for 44 consecutive years.
The affirmation of the Market Perform rating and the $323.00 price target indicates that Bernstein’s outlook on CIGNA’s stock remains steady. This assessment reflects the analysts’ view that the stock is expected to perform in line with the broader market expectations.
CIGNA Corporation, a global health service company, continues to be a significant player in the healthcare industry. With the latest leadership changes and the ongoing endorsement from Bernstein analysts, the company maintains its position in the market.
In other recent news, The Cigna Group announced significant changes to its leadership team, appointing Brian Evanko as President and Chief Operating Officer and Ann Dennison as Executive Vice President and Chief Financial Officer. These changes are part of Cigna’s strategy to enhance customer focus and growth. The company also reaffirmed its financial outlook for 2025, projecting a consolidated adjusted income from operations of at least $29.50 per share. Meanwhile, Piper Sandler adjusted its outlook on Cigna by lowering the stock price target from $394 to $348, following a fourth-quarter earnings shortfall in 2024. Despite this, the firm maintained an Overweight rating on the stock. Additionally, the Department of Justice’s investigation into UnitedHealth Group (NYSE:UNH)’s Medicare billing practices has raised concerns across the healthcare sector, impacting companies like Cigna. In another development, President Trump’s supportive comments on social programs led to a modest rise in Cigna’s stock, reflecting investor confidence in the sector. Cigna also announced executive changes to improve health outcomes, linking executive compensation to customer satisfaction and planning to publish a Customer Transparency Report in 2026.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.